tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2020 Dec;9(1):2361-2367.
doi: 10.1080/22221751.2020.1837017.
A SARS-CoV-2 variant with the 12-bp deletion at E gene
Yi-Sheng Sun[SUP] 1 [/SUP], Fang Xu[SUP] 1 [/SUP], Qi An[SUP] 2 [/SUP], Chen Chen[SUP] 1 [/SUP], Zhang-Nv Yang[SUP] 1 [/SUP], Hang-Jing Lu[SUP] 1 [/SUP], Jian-Cai Chen[SUP] 1 [/SUP], Ping-Ping Yao[SUP] 1 [/SUP], Jian-Min Jiang[SUP] 1 [/SUP], Han-Ping Zhu[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing and has become an important public health threat. This disease is caused by a new coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and so far, little is known about this virus. In this study, by using plaque purification, we purified two SARS-CoV-2 virus strains from the same specimen, one named F8 containing a 12-bp deletion in the E gene and the other named 8X containing the wild-type E gene. There was no significant difference in the viral titer and infectivity of these two strains. The S protein content of the F8 viral culture was 0.39 μg/ml, much higher than that of 8X. An inactivated vaccine made from the F8 strain could trigger high levels of the IgG titer and neutralizing antibody titer, which could last for at least 6 weeks and were significantly higher than those from the 8X strain at 1 and 3 weeks post vaccination, respectively. In conclusion, we reported that both the E gene mutant and wild-type SARS-CoV-2 strains were isolated from the same clinical sample by plaque purification. A 12-bp deletion in the E gene was important for SARS-CoV-2 replication and immunogenicity.
Keywords: COVID-19; E gene mutant; SARS-CoV-2; immunogenicity; virus replication.
. 2020 Dec;9(1):2361-2367.
doi: 10.1080/22221751.2020.1837017.
A SARS-CoV-2 variant with the 12-bp deletion at E gene
Yi-Sheng Sun[SUP] 1 [/SUP], Fang Xu[SUP] 1 [/SUP], Qi An[SUP] 2 [/SUP], Chen Chen[SUP] 1 [/SUP], Zhang-Nv Yang[SUP] 1 [/SUP], Hang-Jing Lu[SUP] 1 [/SUP], Jian-Cai Chen[SUP] 1 [/SUP], Ping-Ping Yao[SUP] 1 [/SUP], Jian-Min Jiang[SUP] 1 [/SUP], Han-Ping Zhu[SUP] 1 [/SUP]
Affiliations
- PMID: 33118859
- DOI: 10.1080/22221751.2020.1837017
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing and has become an important public health threat. This disease is caused by a new coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and so far, little is known about this virus. In this study, by using plaque purification, we purified two SARS-CoV-2 virus strains from the same specimen, one named F8 containing a 12-bp deletion in the E gene and the other named 8X containing the wild-type E gene. There was no significant difference in the viral titer and infectivity of these two strains. The S protein content of the F8 viral culture was 0.39 μg/ml, much higher than that of 8X. An inactivated vaccine made from the F8 strain could trigger high levels of the IgG titer and neutralizing antibody titer, which could last for at least 6 weeks and were significantly higher than those from the 8X strain at 1 and 3 weeks post vaccination, respectively. In conclusion, we reported that both the E gene mutant and wild-type SARS-CoV-2 strains were isolated from the same clinical sample by plaque purification. A 12-bp deletion in the E gene was important for SARS-CoV-2 replication and immunogenicity.
Keywords: COVID-19; E gene mutant; SARS-CoV-2; immunogenicity; virus replication.